Modeling sleep data for a new drug in development using Markov mixed-effects models

Pharmaceutical Research

Volumn 28, Issue 10, 2011, Pages 2610-2627

  Kjellsson, Maria C ^a   Ouellet, Daniele ^b,c   Corrigan, Brian ^d   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b PFIZER INC   (United States)

^c GLAXOSMITHKLINE   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Markov model; NONMEM; pharmacodynamics; polysomnography; population analysis; sleep; transition model; zolpidem

Indexed keywords

HYPNOTIC AGENT; PD 0200390; PLACEBO; UNCLASSIFIED DRUG; ZOLPIDEM;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HUMAN; INSOMNIA; MALE; MODEL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP; SLEEP DURATION; SLEEP PATTERN; SLEEP STAGE; SLEEP TIME; SLOW WAVE SLEEP; WAKEFULNESS;

ACETIC ACIDS; ADULT; CROSS-OVER STUDIES; CYCLOPENTANES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LINEAR MODELS; MALE; MARKOV CHAINS; MIDDLE AGED; POLYSOMNOGRAPHY; PYRIDINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES;

EID: 80054719165     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0490-x     Document Type: Article

References (20)

1. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles: U.B.I.S.B.R. Institute; 1968.
2. B Kemp HA Kamphuisen 1986 Simulation of human hypnograms using a Markov chain Sleep 9 405 14 3764288 1:STN:280:DyaL2s%2FhvVCruw%3D%3D (Pubitemid 18026023)
3. MO Karlsson RC Schoemaker B Kemp AF Cohne JM van Gerven B Tuk CC Peck M Danhof 2000 A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep Clin Pharmacol Ther 68 175 88 10976549 10.1067/mcp.2000. 108669 1:CAS:528:DC%2BD3cXmsFalsr8%3D (Pubitemid 30659173)
4. R Bizzotto S Zamuner G de Nicolao MO Karlsson R Gomeni 2010 Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients J Pharmacokinet Pharmacodyn 37 137 55 20052524 10.1007/s10928-009-9148-2
5. DJ Dooley CP Taylor S Donevan D Feltner 2007 Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission Trends Pharmacol Sci 28 75 82 17222465 10.1016/j.tips.2006.12.006 1:CAS:528:DC%2BD2sXhtlCmu7k%3D (Pubitemid 46161838)
6. DJ Greenblatt JS Harmatz LL von Moltke BL Ehrenberg L Harrel K Corbett M Counihan JA Graf M Darwish PT Martin WH Cevallos RI Shader 1998 Comparative kinetics and dynamics of zaleplon, zolpidem and placebo Clin Pharmacol Ther 64 553 61 9834048 10.1016/S0009-9236(98)90139-4 1:CAS:528:DyaK1cXnvFSitLw%3D (Pubitemid 28531600)
7. B Corrigan J Werth C Bramson C Alvey R Abel D Feltner D Ouellet 2008 Pharmacokinetics and pharmacodynamics of PD 0200390 following single dose administration to healthy volunteers Clin Pharmacol Ther 83 S1 PI-69
8. B Corrigan J Werth A Moton C Alvey D Feltner D Ouellet 2008 Pharmacokinetics of PD 0200390 following multiple dose administration to healthy volunteers Clin Pharmacol Ther 83 S1 PI-71
9. LB Sheiner DR Stanski S Vozeh RD Miller J Ham 1979 Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine Clin Pharmacol Ther 25 358 71 761446 1:CAS:528:DyaE1MXhsl2qsro%3D (Pubitemid 9164953)
10. A Durand JT Thénot G Bianchetti PL Morselli 1992 Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem Drug Metab Rev 24 239 66 1576937 10.3109/03602539208996294 1:CAS:528: DyaK38XktF2lu70%3D
11. A Patat S Trocherie JJ Thebault P Rosenzweig C Dubrac G Bianchetti LA Court PL Morselli 1994 EEG profile of intravenous zolpidem in healthy volunteers Psychopharmacology (Berl) 114 138 46 10.1007/BF02245455 1:CAS:528: DyaK2cXjtFGksbs%3D (Pubitemid 24150531)
12. KJ Holm KL Goa 2000 Zolpidem, An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia Drug 59 865 889 10.2165/00003495-200059040-00014 1:CAS:528:DC%2BD3cXjsVOmu7s%3D (Pubitemid 30232327)
13. DR Dover 2004 Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives. Zaleplon, zolpidem and zopiclone Clin Pharmacokinet 43 227 238 10.2165/00003088-200443040-00002 (Pubitemid 38429303)
14. RM Savic MO Karlsson 2009 Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions AAPS J 11 558 569 19649712 10.1208/s12248-009-9133-0
15. R Development Core Team. R: A language and environment for statistical computing. Vienna: R foundation for statistical computing; 2005.
16. Beal SL, Sheiner LB (eds). NONMEM Users Guides. Elliot City, Maryland, USA: Icon Development Solutions; 1989-98.
17. Gelman A, Carlin JB, Stern HS. Bayesian data analysis. London: Chapman & Hall; 1995.
18. P Girard TF Blaschke H Kastrissios LB Sheiner 1998 A Markov mixed effect regression model for drug compliance Stat Med 17 2313 33 9819830 10.1002/(SICI)1097-0258(19981030)17:20<2313::AID-SIM935>3.0.CO;2-V 1:STN:280:DyaK1M%2Fjslaltw%3D%3D (Pubitemid 28482676)
19. HM Agnew WB Webb RL Williams 1966 The first night effect: an EEG study of sleep Psychophysiology 2 263 6 5903579 10.1111/j.1469-8986.1966.tb02650.x
20. EN Jonsson MO Karlsson 1998 Automated covariate model building within NONMEM Pharm Res 15 1463 8 9755901 10.1023/A:1011970125687 1:CAS:528: DyaK1cXmtFyhu7o%3D (Pubitemid 28427937)